Quick Answer
Inmune Bio, Inc. reported Total Revenue of $50.0 thousand for fiscal year 2025.
Inmune Bio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $50.0K +257.1% |
$14.0K -91.0% |
$155.0K -58.6% |
$374.0K +106.6% |
$181.0K +1545.5% |
$11.0K |
| Net Income | -$45.93M -9.2% |
-$42.08M -40.2% |
-$30.01M -9.9% |
-$27.30M +10.0% |
-$30.34M -150.8% |
-$12.10M -57.6% |
| Diluted EPS | -$1.86 +11.8% |
-$2.11 -26.3% |
-$1.67 -9.9% |
-$1.52 +19.1% |
-$1.88 | — |
| Total Assets | $32.35M -18.2% |
$39.56M -30.6% |
$57.00M -30.3% |
$81.80M -18.2% |
$99.94M +145.8% |
$40.66M +66.1% |
| Cash and Equivalents | $24.75M +18.3% |
$20.92M -41.6% |
$35.85M -31.3% |
$52.15M -30.3% |
$74.81M +240.6% |
$21.97M +214.0% |
| Long-Term Debt | — | — | — | $9.70M | — | — |
| Stockholders Equity | $23.52M -26.7% |
$32.10M -14.0% |
$37.34M -37.9% |
$60.10M -25.1% |
$80.22M +107.0% |
$38.75M +64.1% |
| R&D Expense | $20.66M -37.7% |
$33.17M +63.6% |
$20.27M +18.8% |
$17.07M -16.9% |
$20.54M +247.1% |
$5.92M +80.3% |
| Operating Income | -$47.38M -11.1% |
-$42.63M -43.4% |
-$29.74M -14.6% |
-$25.95M +11.0% |
-$29.15M -138.4% |
-$12.23M -57.7% |
| Shares Outstanding | 26.59M +19.3% |
22.28M +24.1% |
17.95M +0.0% |
17.95M +0.6% |
17.84M +32.4% |
13.48M +25.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2025 | $50.0K | +257.1% | +257.1% |
| Net Income | September 30, 2025 | -$6.47M | +46.5% | +73.5% |
| Diluted EPS | September 30, 2025 | -$0.24 | +60.0% | +77.1% |
| Total Assets | September 30, 2025 | $33.36M | -36.8% | -11.5% |
| Cash and Equivalents | September 30, 2025 | $27.73M | -17.3% | -16.9% |
| Stockholders Equity | September 30, 2025 | $25.38M | -34.4% | -12.1% |
| R&D Expense | September 30, 2025 | $4.89M | -51.5% | -15.8% |
| Operating Income | September 30, 2025 | -$7.43M | +39.5% | +69.7% |
| Shares Outstanding | September 30, 2025 | 26.59M | +19.9% | +0.0% |
- Inmune Bio, Inc. reported Total Revenue of $50.0 thousand for fiscal year 2025.
- Inmune Bio, Inc. showed an increase of +257.1% in Total Revenue compared to the prior fiscal year.
- Inmune Bio, Inc. reported Net Income of -$45.93 million for fiscal year 2025.
- Inmune Bio, Inc. showed a decrease of -9.2% in Net Income compared to the prior fiscal year.
- Inmune Bio, Inc. reported Diluted EPS of $1.86 per share (loss) for fiscal year 2025.
- Inmune Bio, Inc. showed an increase of +11.8% in Diluted EPS compared to the prior fiscal year.
- Inmune Bio, Inc. reported Total Assets of $32.35 million for fiscal year 2025.
- Inmune Bio, Inc. showed a decrease of -18.2% in Total Assets compared to the prior fiscal year.
- Inmune Bio, Inc. reported Cash and Equivalents of $24.75 million for fiscal year 2025.
- Inmune Bio, Inc. showed an increase of +18.3% in Cash and Equivalents compared to the prior fiscal year.
- Inmune Bio, Inc. reported Long-Term Debt of $9.70 million for fiscal year 2022.
- Inmune Bio, Inc. reported Stockholders Equity of $23.52 million for fiscal year 2025.
- Inmune Bio, Inc. showed a decrease of -26.7% in Stockholders Equity compared to the prior fiscal year.
- Inmune Bio, Inc. reported R&D Expense of $20.66 million for fiscal year 2025.
- Inmune Bio, Inc. showed a decrease of -37.7% in R&D Expense compared to the prior fiscal year.
- Inmune Bio, Inc. reported Operating Income of -$47.38 million for fiscal year 2025.
- Inmune Bio, Inc. showed a decrease of -11.1% in Operating Income compared to the prior fiscal year.
- Inmune Bio, Inc. reported Shares Outstanding of 26.59 million shares for fiscal year 2025.
- Inmune Bio, Inc. showed an increase of +19.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: